Vertical tiny homes redefine compact living
Do you prefer the verticality of city apartments but wish you could also own a standalone home? These innovative prefab towers from the German company Moduleform make that possible.
Named the DQ Tower, this micro-living residence is designed for backyards and small urban lots. With three stories, two bedrooms, two bathrooms, and high-end built-in features, it brings a sleek new take on compact living, even if it comes at a premium price.
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my CYBERGUY.COM/NEWSLETTER
With three full stories of living space, the DQ Tower stands over 28 feet tall. However, all that vertical space only takes up a footprint of just 13 by 13 feet. It's designed for tight urban plots or backyard spaces, and instead of spreading out like a traditional mobile tiny home, it rises straight up.
The ground floor opens up into a spacious living and dining area. A comfy sofa pulls double duty as both seating and an optional spare sleeping space. A comfortable dining nook sits next to a kitchenette complete with an induction stove, sink, and refrigerator. The floor-to-ceiling glass windows give plenty of natural light and open up the space even further. The ground floor rounds out with a half bathroom with a convenient washing machine included.
Climbing the staircase to the second floor, you will find the first cozy bedroom complete with a single bed and a built-in wardrobe. On the second floor is also a full bathroom with a standing shower. And yes, the ceilings are quite tall and spacious, avoiding the cramped loft designs of other tiny homes.
The third floor is the showstopper. As you ascend the steel and wood staircase, the master bedroom sits comfortably with a double bed, an even larger wardrobe, and a small desk for a working area. The tall windows up here continue to provide light and ventilation, making the most of the compact space while providing breathtaking views.
In total, the DQ Tower offers nearly 420 square feet of living space. That is a reasonable accommodation for a couple or small family, or anyone who appreciates the efficiency of downsizing. Another option, and one that the manufacturers advertise, is the DQ Tower, which fits comfortably in the backyard, making for a cost-effective and low-impact guest house, perfect for rental sites like Airbnb. And with two bathrooms and two bedrooms, it's surprisingly livable for such a small footprint.
The major convenience and cost-cutting feature of these tiny tower homes is that they come prefabricated. They are built off-site in Germany, transported to the site, and settled into place with a small crane crew. As of now, it takes about eight months from order to delivery. The whole structure is constructed with a sturdy steel frame, well-insulated walls, and clad in chic aluminum panels.
The starting price for these private towers is currently roughly $176,000. Now, that is nearly twice the per-square-foot cost of other tiny homes. However, the DQ Tower offers ultra-high-quality, designer-level micro-living with a sleek and accommodating design.
The DQ Tower is more than just a tiny home. It offers a bold vision for how people can live in smaller spaces without giving up comfort or style. Although it is not currently available in the United States, it provides a clear picture of where compact, vertical living could be headed. As cities become more crowded and backyard space gains value, this European design could inspire the next generation of American prefab housing.
Would you trade square footage for sky-high design if it meant living smarter, smaller, and more sustainably? Let us know by writing us at Cyberguy.com/Contact
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my CYBERGUY.COM/NEWSLETTER
Copyright 2025 CyberGuy.com. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
4 hours ago
- Yahoo
Intel (INTC) Stock Trades Down, Here Is Why
What Happened? Shares of computer processor maker Intel (NASDAQ:INTC) fell 9.6% in the afternoon session after the company reported an unexpected second-quarter loss and announced significant restructuring plans, including major job cuts. While the chipmaker's revenue of roughly $12.8 billion beat forecasts, it posted an adjusted loss of $0.10 per share, which missed Wall Street's expectations for a small profit. In response to the results, Intel announced major cost-cutting measures, including plans that involved a 15% reduction of its global workforce and the cancellation of chip factory projects in Germany and Poland. New CEO Lip-Bu Tan stated the company had "invested too much, too soon—without adequate demand." The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Intel? Access our full analysis report here, it's free. What Is The Market Telling Us Intel's shares are extremely volatile and have had 35 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 4 days ago when the stock gained 3.2% on the news that Stifel raised its price target on the company, adding to investor optimism ahead of its quarterly earnings report this week. Stifel lifted its price target on Intel to $24.50 from $21.00, while maintaining a "Hold" rating on the shares. The move comes as investors and analysts keenly await the company's second-quarter results. According to the analyst note, investor focus will likely be on the company's long-term strategy, including updates on its advanced 18A and 14A chip production processes and efforts to restructure its portfolio. Intel is up 1.8% since the beginning of the year, but at $20.58 per share, it is still trading 34.4% below its 52-week high of $31.35 from July 2024. Investors who bought $1,000 worth of Intel's shares 5 years ago would now be looking at an investment worth $415.17. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
5 hours ago
- Yahoo
Bayern Munich's Adam Aznou scheduled for Everton medical this weekend
Everton should be able to wrap up a purchase of Bayern Munich fullback Adam Aznou soon. Sport Bild reports that the 19-year-old has indeed lodged a transfer request with his Bundesliga club. Earlier this week, Kicker confirmed that Bayern's previous negotiations with Getafe CF had produced nothing but a busted deal, Fabrizio Romano now reports that the German and English club have reached full agreement on the transfer. Romano confirms numbers originating in a report from The Athletic earlier today. Bayern shall receive a base-transfer-fee for their young talent. An additional €3m in bonuses have beeb tacked on. Aznou, per Romano, will undergo his Everton medical this weekend. Aznou was recalled by Bayern Munich early from his recent loan stint with Real Valladolid in order to participate in the recent club World Cup. The teenager nevertheless wasn't able to take advantage of the opportunity accorded to him. Aznou logged only eight minutes as a substitute in Bayern's opening group stage fixture. GGFN |
